Advanced Filters
noise

Cypress, California Clinical Trials

A listing of Cypress, California clinical trials actively recruiting patient volunteers.

Found 728 clinical trials
S Site Public Contact

64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to compare its imaging biodistribution with FAP expression by IHC in patients with sarcomas or GIT cancers. The study …

15 years of age All Phase 1/2

A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes

This study is designed to test how well the combination of MET233 with MET097 works to treat individuals with obesity or overweight with or without diabetes.

18 - 75 years of age All Phase 1/2

Phase 1 Study of PRX019 in Healthy Adult Volunteers

The purpose of this study is to assess the safety and tolerability of PRX019 in healthy adult participants.

18 - 65 years of age All Phase 1

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

18 years of age All Phase 4
D Danielle Montano CRC

Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula

VasQ is an external support implant for arteriovenous fistulas created for dialysis access. This is a postmarket surveillance, prospective, multi-center, randomized, controlled, open label trial enrolling 300 patients randomized into two study arms: Treatment arm: End to side fistula supported with VasQ Control: Standard of care end to side fistula

18 - 80 years of age All Phase N/A
A Alan Jazuli

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension

18 - 75 years of age All Phase 2
I Ivan J. Suner, MD

Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

This randomized trial will compare treatment strategies for proliferative diabetic retinopathy (PDR). Participants will receive either combination a of faricimab + PRP or vitrectomy + endolaser. The participants will be followed for 3 years. The study will evaluate long-term visual acuity as well as differences in number of injections, procedures, …

18 years of age All Phase 3

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

This study was planned to determine the effect of virtual reality glasses on anxiety, fear, and physiological parameters in cancer patients aged 4-10 years undergoing intrathecal chemotherapy. The main questions that the study aimed to answer are as follows: Could virtual reality glasses affect the fear experienced by children undergoing …

50 years of age All Phase 3

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)

This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking …

18 - 65 years of age All Phase 3

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer

18 years of age All Phase 2

Simplify language using AI